Blog

Ajay Major: Methylphenidate versus piperonyl butoxide RCT for cancer related fatigue

Photo taken from Patrick Charles Stone/X

Jun 29, 2024, 06:38

Ajay Major: Methylphenidate versus piperonyl butoxide RCT for cancer related fatigue

Ajay Major, Assistant Professor at the University of Colorado School of Medicine and Founder and President at Pager Publications, shared a post on X:

“Methylphenidate versus piperonyl butoxide Randomized Controlled Trial (RCT) for cancer-related fatigue Journal of Clinical Oncology:

162 patients, all incurable cancer with baseline fatigue.
nonsignificant Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) fatigue scores.
no difference in other Quality of Life (QoL) domains.
Important pallonc trial with pro as primary endpoint.”

Source: Ajay Major/X

Ajay Major cancer FACIT-F Journal of Clinical Oncology methylphenidate OncoDaily Oncology piperonyl butoxide randomized controlled trial University of Colorado

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity